Results 11 to 20 of about 1,796 (202)

Venetoclax in the Therapeutic Strategy for BPDCN Management. [PDF]

EJHaem
ABSTRACTBackgroundVenetoclax, a B‐cell lymphoma 2 (BCL‐2) inhibitor, is a promising treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is currently under evaluation in clinical trials. However, several case reports have reported relapses after prolonged treatment, and development of resistance.
Poussard M, Fredon M, Belakri I, Biichle S, Renosi F, Seffar E, Boichut M, Boidot R, Bôle-Richard E, Bonnefoy F, Kroemer M, Bonnot-Perrin S, Saas P, Adotévi O, Garnache-Ottou F, Angelot-Delettre F.   +15 more
europepmc   +5 more sources

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity [PDF]

eJHaem, 2020
AbstractBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these therapies, the influence of one on the other has to be explored.
Poussard, Margaux, Philippe, Laure, Fredon, Maxime, Bôle-Richard, Elodie, Biichle, Sabeha, Renosi, Florian, Perrin, Sophie, Kroemer, Marie, Limat, Samuel, Bonnefoy, Francis, Daguindau, Etienne, Deconinck, Eric, Gruson, Bérengère, Saas, Philippe, Adotévi, Olivier, Garnache-Ottou, Francine, Angelot-Delettre, Fanny   +16 more
openaire   +3 more sources

Acute Myeloid Leukemia With Plasmacytoid Differentiating Cutaneous Lesions: A Case of Double Identity or Active Transformation. [PDF]

EJHaem
ABSTRACT Introduction Acute myeloid leukemia (AML) with plasmacytoid dendritic cell differentiation (pDC‐AML) is a newly described subtype of leukemia with features resembling blastic plasmacytoid dendritic cell neoplasm (BPDCN). Case Presentation Herein, we present a case of pDC‐AML in which bone marrow findings were best classified as AML, whereas ...
Lee BJ, Griffin SP, Jeyakumar D, Gamayo A, Rezk SA, Naqvi K.   +5 more
europepmc   +2 more sources

Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm. [PDF]

Cancer Cell Int
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy originating from precursors of plasmacytoid dendritic cells.
Wang M, Xue X, Wang Z, Wang C, Yu G, Mi Z, Sang X, Wang J, Liu Y, Chen X, Chen S, Zhou G, Liu H, Chen H, Sun Y, Zhang F.   +15 more
europepmc   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm secondary to acute myeloid leukemia with shared mutations in TET2 and DNMT3A: a case report and literature review. [PDF]

Front Immunol
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. Recent studies have highlighted its occurrence in patients with a history of preceding myeloid neoplasms.
Sun Y, Liu Y, Liu N, Zhang X, Huang W, Hu L.   +5 more
europepmc   +2 more sources

First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial. [PDF]

Br J Haematol
British Journal of Haematology, Volume 207, Issue 6, Page 2592-2596, December 2025.
Stein AS, Lane AA, Sweet KL, Vasu S, Tosolini A, Katsetos J, Konopleva M, Pemmaraju N.   +7 more
europepmc   +2 more sources

Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm. [PDF]

Cancer
Abstract Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic neoplasm that expresses CD123, is often observed in the bone marrow (BM), as well as skin, blood, and viscera. Tagraxofusp, a first‐in‐class CD123‐targeted therapy, is the only drug approved to treat BPDCN.
Konopleva M, Pemmaraju N, Sweet KL, Stein AS, Rizzieri DA, Wang ES, Vasu S, Rosenblat T, Zuurman M, Gupta I, Lane AA.   +10 more
europepmc   +2 more sources

Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm

Haematologica, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that presents with characteristic dark purple skin papules, plaques, and tumors, but may also involve the bone marrow, blood, lymph nodes, and central nervous system ...
Marlise R. Luskin, Andrew A. Lane
doaj   +1 more source

Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base. [PDF]

Leuk Res Rep
BPDCN is an aggressive myeloid malignancy characterized by unique expression of CD123, CD4, CD56, CD303, CD304, TCL1 and TCF4. The development of tagraxofusp, a CD123-directed cytotoxin, has revolutionized BPDCN treatment, especially for patients unfit ...
Krah NM, Hoeg R, Shami PJ, Elf SE, Lee LE, Pemmaraju N, Patel AB.   +6 more
europepmc   +2 more sources

Regimen of Azacitidine Combined with GemOx in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report

Xiehe Yixue Zazhi, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly malignant hematological tumor derived from the precursor cells of plasmacytoid dendritic cells.
CHEN Xiaojun, LIU Yanquan, HU Xiaomei, HUANG Surong, SHEN Jianzhen   +4 more
doaj   +1 more source